Evidence map›Paper›PMID 37875670›Full record

ArticleBreast cancer research and treatment2024

Changes in cell-free DNA after short-term palbociclib and fulvestrant treatment for advanced or metastatic hormone receptor-positive and human epidermal growth factor 2-negative breast cancer.

Takayuki Iwamoto, Naoki Niikura, Kenichi Watanabe, Takashi Takeshita, Yuichiro Kikawa, Kokoro Kobayashi, Nobutaka Iwakuma, Takuho Okamura, Hiroshi Tada, Shinji Ozaki and 7 more

Abstract read
PubMed Publisher
In one paragraph

Article in Breast cancer research and treatment, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 16 institutions in 1 country.

Takayuki IwamotoBreast and Thyroid Surgery, Kawasaki Medical School Hospital, 577 Matsushima, Kurashiki City, Okayama, 701-0192, Japan. tiwamoto@med.kawasaki-m.ac.jp.ORCID http://orcid.org/0000-0001-5835-5160
Naoki NiikuraDepartment of Breast Oncology, Tokai University School of Medicine, Isehara, Kanagawa, Japan.
Kenichi WatanabeBreast Surgery, Hokkaido Cancer Center, Sapporo, Hokkaido, Japan.
Takashi TakeshitaBreast and Endocrine Surgery, Kumamoto City Hospital, Kumamoto, Kumamoto, Japan.
Yuichiro KikawaDepartment of Breast Surgery, Kansai Medical University Hospital, Hirakata, Osaka, Japan.
Kokoro KobayashiDepartment of Medical Oncology, Saitama Red Cross Hospital, Saitama, Saitama, Japan.
Nobutaka IwakumaBreast Center, Department of Breast Surgery, Kyushu Medical Center, Fukuoka, Fukuoka, Japan.
Takuho OkamuraDepartment of Breast Oncology, Tokai University School of Medicine, Isehara, Kanagawa, Japan.
Hiroshi TadaDepartment of Surgery, Division of Breast and Endocrine Surgery, Tohoku University Hospital, Sendai, Miyagi, Japan.
Shinji OzakiDepartment of Gastrointestinal and Breast Surgery, Hiroshima Prefectural Hospital, Hiroshima, Hiroshima, Japan.
Toshitaka OkunoDepartment of Breast Surgery, Kobe City Nishi-Kobe Medical Center, Kobe, Hyogo, Japan.
Uhi TohDepartment of Breast Surgery, Kurume University Hospital, Kurume, Fukuoka, Japan.
Yutaka YamamotoDepartment of Breast and Endocrine Surgery, Kumamoto University Hospital, Kumamoto, Kumamoto, Japan.
Michiko TsuneizumiDepartment of Breast Surgery, Shizuoka General Hospital, Shizuoka, Shizuoka, Japan.
Hiroshi IshiguroBreast Oncology Service, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan.
Norikazu MasudaDepartment of Breast and Endocrine Surgery, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
Shigehira SajiDepartment of Medical Oncology, Fukushima Medical University School of Medicine, Fukushima, Fukushima, Japan.
Tokai University · JPFukushima Medical University · JPHiroshima Prefectural Hospital · JPHokkaido University Hospital · JPKansai Medical University · JPKawasaki Medical School · JPKobe City Nishi-Kobe Medical Center · JPKumamoto City Hospital · JPKumamoto University Hospital · JPKurume University Hospital · JPNagoya University · JPNational Kyushu Medical Center · JPSaitama Medical University · JPSaitama Red Cross Hospital · JPShizuoka General Hospital · JPTohoku University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeHere, we investigated the potential predictive and elucidating efficacy of cell-free DNA (cfDNA) changes on clinical outcomes and biological effects, respectively, after short-term palbociclib and fulvestrant treatment for patients with hormone receptor (HR)-positive and human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer (ABC).

methodsIn this secondary analysis of the Japan Breast Cancer Research Group-M07 (FUTURE) trial, blood cfDNA was obtained before palbociclib treatment and on day 15 of cycle one (28-day cycle). Target enrichment was performed using next-generation sequencing; progression-free survival (PFS) was compared based on cfDNA changes between baseline and day 15 of cycle one after combination therapy.

resultsFifty-six patients (112 paired blood samples) were examined. The median follow-up time was 8.9 months. PIK3CA (30.4%, 17/56), FOXA1 (30.4%, 17/56), and ESR1 (28.6%, 16/56) were most frequently mutated at baseline. The number of mutated genes was significantly decreased on day 15 compared with that at baseline (paired t test: P value = 0.025). No significant difference was observed in PFS (decrease group, 7.9 m vs the others, 9.3 m; log-rank P value = 0.75; hazard ratio, 1.13; 95% confidence interval, 0.53-2.41). Among patients without previous aromatase inhibitor treatment (n = 15), three (20%) had ESR1 mutations after progression to fulvestrant.

conclusionNo significant association was observed between changes in mutated genes after short-term palbociclib and fulvestrant treatment and disease progression; a significant reduction in cfDNA mutation level was observed on day 15 of cycle one. Clinical meanings of cfDNA should be investigated in the future trials.

Indexed as

Breast NeoplasmsCell-Free Nucleic AcidsPiperazinesPyridinesTriple Negative Breast NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsDisease-Free SurvivalEpidermal Growth FactorErb-b2 Receptor Tyrosine KinasesFemaleFulvestrantHumansCell-Free Nucleic AcidsEpidermal Growth FactorErb-b2 Receptor Tyrosine KinasesFulvestrantpalbociclibPiperazinesPyridinesAdvanced breast cancerCell-free DNAFulvestrantPalbociclibWindow of opportunity

Identifiers

PMID37875670
OpenAlexW4387931082

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.